Update on current applications of proteomic in the study of inflammatory bowel disease

Annals of Gastroenterology

Volumn 25, Issue 4, 2012, Pages 303-308

  Roda, Giulia ^a   Caponi, Alessandra ^a   Sartini, Alessandro ^a   Cevenini, Monica ^a   Colliva, Carolina ^b   Roda, Aldo ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Biomarkers; Crohn's disease; Metabolomic; Nutrigenomic; Proteomic; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

BIOINFORMATICS; BLOOD ANALYSIS; CROHN DISEASE; ENTERITIS; HISTOLOGY; HUMAN; INTESTINE CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; NUTRIGENOMICS; PLATELET MICROPARTICLE; PROTEIN ANALYSIS; PROTEOMICS; QUORUM SENSING; REVIEW;

EID: 84869036233     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011;140:1729-1737.
2. Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis 2010;28:418-423.
3. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140:1817-1826. e2.
4. Beniwal P, Harrell L. The status of diagnostic markers for inflammatory bowel disease. Curr Gastroenterol Rep 2010;12:479-484.
5. Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol 2004;20:318-327.
6. Price A. Overlap in the spectrum of non-specific inflammatory bowel disease-'colitis indeterminate'. J Clin Pathol 1978;31:567-577.
7. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122:1242-1247.
8. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic or unnecessary toys? Gut 2006;55:426-431.
9. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation on inflammatory bowel disorders from constipation and diarrhoea predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002;14: 409-412.
10. Koelewijn CL, Schwartz MP, Samsom M, et al. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008;14:85-89.
11. Saxon A, Shanahan F, Landers C, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990;86:202-210.
12. Eggena M, Targan SR, Iwanczyk L, et al. Phage display cloning and characterization of an immunogenetic marker (perinuclear anti-neutrophil cytoplasmic antibody) in ulcerative colitis. J Immunol 1996;156:4005-4011.
13. Eggena M, Cohavy O, Parseghian MH, et al. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J Autoimmun 2000;14:83-97.
14. Vecchi M, Sinico A, Bianchi MB, et al. Recognition of bactericidial/ permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance. Scand J Gastroenterol 1998;33:1284-1288.
15. Papp M, Norman GL, Altorjay I, et al. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol 2007;13:2028-2036.
16. Mainardi E, Villanacci V, Bassotti G, et al. Diagnostic value of serological assays in pediatric inflammatory bowel disorders. Digestion 2007;75:210-214.
17. Foley KF, Kao P. Biomarkers for inflammatory bowel disease. Clin Lab Sci 2007;20:84-88.
18. Joossens S, Colombel JF, Vermeire S, et al. Panel of serologic antibodies in patients with indeterminate colitis. Gastroenterology 2003;124:A323.
19. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-496.
20. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001;7:8-15.
21. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996;110:1810-1819.
22. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behaviour, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008;103:665-681.
23. Kim BC, Park S, Han J, et al. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course. Dig Liver Dis 2007;39:610-616.
24. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007;56:1394-1403.
25. Klebl FH, Bataille F, Bertea CR, et al. Association of perinuclear anti-neutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis 2003;9:302-307.
26. Sandborn WJ, Landers CJ, Tremaine WJ, et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996;71:431-436.
27. Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001;120:1347-1355.
28. Barahona-Garrido J, Camacho-Escobedo J, García-Martínez CI, Tocay H, Cabiedes J, Yamamoto-Furusho JK. Antinuclear antibodies: a marker associated with steroid dependence in patients with ulcerative colitis. Inflamm Bowel Dis 2009;15:1039-1043.
29. Angriman I, Scarpa M, D'Incà R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007;381:63-68.
30. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008;51:1283-1291.
31. Xiang JY, Ouyang Q, Li GD, et al. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008;14:53-57.
32. Peterson CG, Sangfelt P, Wagner M, et al. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest 2007;67:810-820.
33. Shitrit AB, Braverman D, Stankiewics H, et al. Fecal calprotectin as a predictor of abnormal colonic histology. Dis Colon Rectum 2007;50:2188-2193.
34. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;32:171-177.
35. Sipponem T, Savilahti E, Kärkkäinen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14:1392-1398.
36. Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:414-422.
37. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:14-22.
38. Bjarnason I, Sherwood R. Fecal calprotectin: a significant step in the non-invasive assessment of intestinal inflammation. J Pediatr Gastroenterol Nutr 2001;33:11-13.
39. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
40. Wittmann-Liebold B, Graack HR, Pohl T. Two dimensional gel electrophoresis as tool for proteomics studies in combination with protein identification by mass spectrometry. Proteomics 2006;6:4688-4703.
41. Bantscheff M, Schirle M, Sweetman G, et al. Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem 2007;389:1017-1031.
42. Iliuk A, Galan J, Tao WA. Playing tag with quantitative proteomics. Anal Bioanal Chem 2009;393:503-513.
43. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17:994-999.
44. Apweiler R. Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med 2009;47:724-744.
45. Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol 2008;14:5115-5124.
46. Alex P, Gucek M, Li X. Applications of proteomics in the study of inflammatory bowel disease: current status and future directions with available technologies. Inflamm Bowel Dis 2008;4:616-629.
47. Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol 2007;73:1422-1433.
48. Meuwis MA, Fillet M, Lutteri L, et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem 2008;41:960-967.
49. Nanni P, Parisi D, Roda G, et al. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-offlight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom 2007;21:4142-4148.
50. Barcelo-Batllori S, André M, Servis C, et al. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics 2002;2:551-560.
51. Felley-Bosco E, André M. Proteomics and chronic inflammatory bowel diseases. Pathol Res Pract 2004;200:129-133.
52. Hardwdige P, Rodriguez-Escudero I, Goode D, et al. Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli. J Biol Chem 2004;279:20127-20136.
53. Shkoda A, Werner T, Daniel H, et al. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J Proteome Res 2007;6:1114-1125.
54. Fogt F, Jian BO, Krieg RC, et al. Proteomic analysis of mucosal preparations from patients with ulcerative colitis. Mol Med Reports 2008;1:51-54.
55. Hsieh SY, Shih TC, Yeh CY, et al. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 2006;6:5322-5331.
56. Liu BG, Cao YB, Cao YY. Altered protein profile of lymphocytes in an antigen-specific model of colitis: a comparative proteomic study. Inflamm Res 2007;56:377-384.
57. Berndt U, Bartsch S, Philipsen L, et al. Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis. J Immunol 2007;179:295-304.
58. M'Koma AE, Seeley EH, Washington MK, et al. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflamm Bowel Dis 2011;17:875-883.
59. Huber LA, Pfaller K, Vietor I. Organelle proteomics: implications for subcellular fractionation in proteomics. Circ Res 2003;92:962-968.
60. Groen AJ, de Vries SC, Lilley KS. A proteomics approach to membrane trafficking. Plant Physiol 2008;147:1584-1589.
61. O'Morain C, Smethurst P, Levi J, et al. Subcellular fractionation of rectal biopsy homogenates from patients with inflammatory bowel disease. Scand J Gastroenterol 1985;20:209-214.
62. Nanni P, Mezzanotte L, Roda G, et al. Differential proteomic analysis of HT29 Cl.16E and intestinal epithelial cells by LC ESI/QTOF mass spectrometry. J Proteomics 2009;72:865-873.
63. Andoh A, Yoshida T, Yagi Y, et al. Increased aggregation response of platelets in patients with inflammatory bowel disease. J Gastroenterol 2006;41:47-54.
64. Chamouard P, Desprez D, Hugel B, et al. Circulating cellderivedmicroparticles in Crohn's disease. Dig Dis Sci 2005;50:574-580.
65. Andoh A, Tsujikawa T, Hata K, et al. Elevated circulating plateletderived microparticles in patients with active inflammatory bowel dis-ease. Am J Gastroenterol 2005;100:2042-2048.
66. Srirajaskanthan R, Winter M, Muller AF. Venous thrombosis in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2005;17:697-700.
67. Choi SK, Kasturi L, Tavakoly A, Safier HL. Ulcerative colitis diagnosed in a patient with venous thromboembolism. Hosp Physician 2008;44:32-36.
68. Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005;3:617-628.
69. Pap E, Pállinger E, Pásztói M, Falus A. Highlights of a new type of intercellular communication: microvesicle-based information transfer. Inflamm Res 2009;58:1-8.
70. Huber V, Fais S, Iero M, et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005;128:1796-1804.
71. Nanni P, Levander F, Roda G. A label-free nano-liquid chromatography-mass spectrometry approach for quantitative serum peptidomics in Crohn's disease patients. J Chromatogr B Analyt Technol Biomed life Sci 2009;877:3127-3136.
72. Murdoch TB, Fu H, Farlane SM, et al. Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. Anal Chem 2008;80:5524-5531.
73. Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007;6:546-551.
74. Ooi M, Nishiumi S, Yoshie T, et al. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res 2011;60:831-40.
75. Kumari A, Pasini P, Daunert S. Detection of bacterial quorum sensing N-acyl homoserine lactones in clinical samples. Anal Bioanal Chem 2008;391:1619-1627.
76. Haller D. Nutrigenomics and IBD: the intestinal microbiota at the cross-road between inflammation and metabolism. J Clin Gastroenterol 2010;44 (Suppl 1):S6-S9.